Glucare XR 750 mg is a prescription oral hypoglycemic medication formulated to manage chronic hyperglycemia in adult patients diagnosed with Type 2 Diabetes Mellitus. Metformin Hydrochloride within a specialized matrix system.
Unlike immediate-release formulations, the extended-release design ensures a gradual, continuous dissolution of the active drug in the gastrointestinal tract. This provides steady systemic plasma concentrations over a 24-hour period, helping to stabilize glycemic control while significantly reducing the incidence of acute gastrointestinal side effects.
Key Medical Benefits & Clinical Value
1. Stabilization of Fasting and Postprandial Blood Glucose
Glucare XR 750 mg targets both baseline fasting plasma glucose and post-meal (postprandial) spikes. By improving glycemic control, the medication helps patients maintain their target hemoglobin A1c (HbA1c) levels, reducing the risk of microvascular and macrovascular complications associated with chronic diabetes.
2. Enhancement of Peripheral Insulin Sensitivity
Patients with Type 2 Diabetes typically suffer from insulin resistance, where cells fail to respond effectively to endogenous insulin. Metformin works at the cellular level to increase peripheral glucose uptake and utilization in skeletal muscle and adipose tissue, enhancing the body's natural metabolic response.
3. Mitigated Risk of Hypoglycemic Episodes
When utilized as a monotherapy, Glucare XR does not stimulate pancreatic insulin secretion. Because it does not forcefully drive down blood glucose below physiological norms, it carries a significantly lower risk of causing acute hypoglycemia (dangerously low blood sugar) compared to sulfonylureas or exogenous insulin.
Ingredients & Mechanism of Action
Active Ingredient: Metformin Hydrochloride (750 mg)
The primary chemical agent is a biguanide compound embedded in a hydrophilic polymer matrix system.
Clinical Mode of Action:
Metformin Hydrochloride lowers blood glucose through three distinct pharmacological mechanisms:
Inhibition of Hepatic Gluconeogenesis: It directly suppresses excess glucose production and output by the liver.
Delayed Intestinal Glucose Absorption: It slows down the rate of glucose absorption across the gastrointestinal mucosa into the bloodstream.
AMPK Activation: It activates adenosine monophosphate-activated protein kinase (AMPK), an enzyme that plays a crucial role in cellular energy balance, thereby promoting glucose transport into insulin-sensitive tissues.
The extended-release matrix ensures that the active compound is released slowly into the intestinal lumen, allowing for superior gastric tolerance and once-daily dosing convenience.
Usage Instructions & Safety Precautions
Clinical Administration Guidelines
Glucare XR 750 mg is a prescription-only medication and must be taken under strict medical supervision.
Dosage: The quantitative regimen must be fully individualized by a registered physician based on current blood glucose measurements and HbA1c profiles.
Administration: Tablets must be swallowed whole with a glass of water. Do not crush, chew, or divide the tablets, as doing so breaks the extended-release matrix and risks releasing the full dose simultaneously.
Timing: For optimal pharmacokinetics and gastrointestinal comfort, administer the daily dose in the evening with a meal.
Crucial Safety Precautions & Contraindications
Renal Function Monitoring: Metformin is cleared primarily through renal excretion. It is strictly contraindicated in patients presenting with severe renal impairment or acute/chronic metabolic acidosis (including diabetic ketoacidosis). Regular assessment of the Estimated Glomerular Filtration Rate (eGFR) is mandatory prior to initiation and annually thereafter.
Lactic Acidosis Warning: Although rare, lactic acidosis is a severe, life-threatening metabolic complication that can occur due to metformin accumulation (often secondary to significant renal decline or acute alcohol intoxication). Symptoms include deep, rapid breathing (hyperventilation), muscle cramps, abdominal pain, and profound malaise. Suspected cases require immediate emergency medical intervention.
Surgical Interventions & Contrast Media: The medication must be temporarily discontinued prior to or at the time of any radiologic imaging procedure involving iodinated contrast media, or before elective surgeries under general anesthesia. Do not resume therapy until at least 48 hours post-procedure, and only after renal function has been re-evaluated and confirmed stable.
Storage Parameters: Store the medication in its original packaging in a dry environment maintained below 30°C. Keep safely out of reach of children.
Brands
